At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 15 enrolled
Drug / intervention
VTS-Kdrug
Likely dose
VTS-K 486mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Clinical Trial of Simultaneous Administration of Oral Aspirin and Ketamine as Adjunct to Oral Antidepressant Therapy in Treatment-Resistant Depression
In Brief
A Phase 4 clinical trial evaluating VTS-K for Treatment Resistant Depression and 12 related conditions. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTreatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine, Peripheral Nervous System Agents, Central Nervous System Depressants, Neurotransmitter Agents, Anti-Inflammatory Agents, Physiological Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptoms
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedNov 2022
Enrollment StartDec 2022
Primary CompletionMay 2024
TodayJul 2026
First PostedNov 14, 2022
Enrollment StartDec 6, 2022
Primary CompletionMay 17, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.6 years ago
Interventions
VTS-Kdrug
Proprietary oral formulation of 486mg aspirin and 80mg ketamine